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Abstract
Background
Deep vein thrombosis (DVT) occurs when a blood clot blocks blood flow through a vein, which can occur after surgery,
trauma, or when a person has been immobile for a long period of time. Clots can dislodge and block blood flow to the lungs
(pulmonary embolism (PE)), causing death. DVT and PE are both known by the term venous thromboembolism (VTE).
Heparin (in the form of unfractionated heparin (UFH) is a blood-thinning drug used in the first three to five days of DVT
treatment. Low molecular weight heparins (LMWH) allow people with DVT to receive their initial treatment at home instead of
in hospital. This is an update of a review first published in 2001 and updated in 2007.
Objectives
To compare the incidence and complications of venous thromboembolism (VTE) in participants treated at home versus
participants treated with standard in-patient hospital regimens. Secondary objectives included patient satisfaction and cost
effectiveness.
Search methods
For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register (last
searched 16 March 2017), CENTRAL (2017, Issue 2), and trials registries. We also checked reference lists of relevant
publications.
Selection criteria
Randomised controlled trials (RCTs) of home versus hospital treatment for DVT in which DVT was clinically confirmed and
treated with either LMWH or UFH.
Data collection and analysis
One review author selected the material for inclusion and another author reviewed the selection of trials. Two review authors
independently extracted data and assessed included studies for risk of bias. Primary outcomes included combined VTE
events (PE and recurrent DVT), gangrene, heparin complications, and death. Secondary outcomes were patient satisfaction
and cost implications. We performed meta-analysis using fixed-effect models with risk ratios (RR) and 95% confidence
intervals (CIs) for dichotomous data.
Main results
Seven RCTs involving 1839 randomised participants with comparable treatment arms were included. All seven had
fundamental problems including high exclusion rates, partial hospital treatment of many in the home treatment arms, and
comparison of UFH in hospital with LMWH at home. The trials showed that patients treated at home with LMWH are less
likely to have recurrence of VTE events compared with hospital treatment with UFH or LMWH (fixed effect risk ratio (RR)
0.58, 95% confidence interval (CI) 0.39 to 0.86; 6 studies; 1708 participants; P = 0.007) (low-quality evidence). No clear
difference was seen between the groups for major bleeding (RR 0.67; 95% CI 0.33 to 1.36; 6 studies; 1708 participants; P =
0.27) (low-quality evidence), minor bleeding (RR 1.29; 95% CI 0.94 to 1.78; 6 studies; 1708 participants; P = 0.11) (low-
quality evidence) or mortality (RR 0.69, 95% CI 0.44 to 1.09; 6 studies; 1708 participants; P = 0.11) (low-quality evidence).
There were no reports of venous gangrene in any of the included studies. Patient satisfaction and quality of life outcomes
could not be combined in meta-analysis due to heterogeneity of reporting, but two of the three studies found evidence that
home treatment had greater improvements in quality of life compared with in-patient treatment at some point during the
follow-up, and the third study reported a large number of participants chose to switch from in-patient care to home-based
care for social and personal reasons, suggesting it is the patient's preferred option (very low-quality evidence). None of the
studies included in the review carried out a full cost effectiveness analysis. However, a small randomised economic
evaluation of the two alternative treatment settings involving 131 participants found that direct costs were higher for those in
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the in-patient group. These findings were supported by three other studies that reported on costs for their studies (very low-
quality evidence).
Quality of evidence of the data from the meta-analyses was low to very low. This was due to risk of bias as many of the
included studies had unclear randomisation techniques, and blinding was a concern for many. Also, there was a concern with
indirectness as a majority of the studies had a large number of participants who were randomised to the home (LMWH)
treatment group that were treated in hospital for some or all of the treatment period. A further issue for some outcomes was
heterogeneity in the measurement and reporting of the outcome.
Authors' conclusions
There is low-quality evidence that patients treated at home with LMWH are less likely to have recurrence of VTE compared
to those treated in the hospital. However, no clear differences in major or minor bleeding, or for mortality, were seen (low-
quality evidence), indicating that home treatment is no worse for these outcomes when compared with in-patient treatment.
Further large trials comparing these treatments are unlikely to occur. Therefore, home treatment is likely to become the norm
and further research will be directed to resolving practical issues such as developing local guidelines which contain clinical
prediction rules, biomarkers and imaging which can be used to tailor therapy to the severity of the disease as well as
development of training for community healthcare workers to administer and monitor treatment progress.
Plain language summary
Home versus in-patient treatment for deep vein blood clots
Background
Deep vein thrombosis (DVT) occurs when a blood clot blocks blood flow through a vein, generally in the legs. This can
happen after surgery, trauma, when a person is immobile for a long period of time, or for no obvious reason. Clots can
dislodge and block blood flow to the lungs (pulmonary embolism (PE)), which can be fatal. DVT and PE are both known as
venous thromboembolism (VTE). Heparin is a blood-thinning drug used to treat DVT during the first three to five days.
Unfractionated heparin (UFH) is administered intravenously in hospital with laboratory monitoring. Low molecular weight
heparins (LMWH) are given by subcutaneous injection once a day and can be given at home. Oral anticoagulants are then
continued for three to six months. After recovery from the acute episode, people may develop post-thrombotic syndrome with
leg swelling, varicose veins and ulceration.
Study characteristics and key results
Seven randomised controlled trials involving 1839 patients with clinically confirmed DVT compared home (LMWH) versus
hospital (heparin, or LMWH in one trial) treatment. Trials had limitations including high exclusion rates and designs that did
not take into account short hospital stays for any of the people who were treated at home to allow fair comparison of heparin
in hospital with LMWH at home.
The trials showed that patients treated at home with LMWH had a lower recurrence of VTE compared with hospital-treated
patients. The review showed no clear difference between the treatment groups for major bleeding, minor bleeding or deaths.
No venous gangrene was reported in any study. We could not pool the information on patient satisfaction and quality of life
as studies had different ways of reporting these, but two of the three studies reporting on quality of life found evidence that
home treatment had greater improvements in quality of life compared with in-patient treatment, at some point during the
follow-up. The third study reported a large number of participants chose to switch from in-patient care to home-based care for
social and personal reasons, indicating that home treatment was more accepted compared with in-patient treatment. Studies
which looked at cost showed that home management had a lower cost per incident of treatment.
Quality of the evidence
Overall, the quality of evidence of the data was low to very low due to risk of bias, indirectness and differences in measuring
and reporting of outcomes. Risk of bias is a concern as many of the included studies did not fully explain how they
randomised and allocated their participants to the treatments and also blinding techniques were not clear. Full blinding would
be difficult if not impossible for these types of treatments (home versus hospital) but there are techniques that could be put in
place such a using the same treatment medications and blinding those who measure the outcomes. Another concern was
that in some studies, participants randomised to home treatment actually ended up being treated in hospital, but remained in
their assigned treatment for the analysis (this is known as indirectness). This makes it hard to determine if the results actually
answer the question of whether home versus hospital treatment for DVT is superior. A further concern for a few of the
outcomes was variation in the way the outcome was measured and reported.
Background 
Description of the condition
Deep vein thrombosis (DVT) is a frequent disorder in western medical practice, affecting one to two per thousand of the
adult population annually. DVT occurs in conjunction with malignancy, after surgery, trauma and immobilisation, and
can occur spontaneously. It manifests in the acute stage with leg symptoms and, in a small minority, with potentially
fatal pulmonary embolism (PE). Venous thromboembolism (VTE) is a term that refers to both DVT and PE. After
recovery from the acute episode, people may develop post-thrombotic syndrome with leg swelling, varicosis and
ulceration. The gold standard techniques for diagnosing DVT are ascending venography and duplex ultrasound
scanning. Deep vein thrombosis is most commonly managed by anticoagulants to prevent spread of the clot proximally
and allow it to become adherent or undergo fibrinolysis, thus reducing the risk of PE. Currently used anticoagulant
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treatment includes unfractionated and low molecular weight heparin (UFH and LMWH, respectively) as well as vitamin
K antagonists (VKA), primarily warfarin, and direct oral anticoagulants (DOACs) (NICE 2012; Robertson 2015; van Es 2014).
Description of the intervention
In the hospitalised patient UFH is usually administered intravenously, with laboratory monitoring for about five days,
overlapping with oral anticoagulants that are continued for three to six months. LMWH is administered daily by subcutaneous
injection, which can be delivered at home without need for continuous laboratory monitoring, also followed by an oral
anticoagulant regimen.
Why it is important to do this review
The development of LMWHs has resulted in many trials investigating their efficaciousness and safety, as compared
with UFH. These studies show that LMWH is at least as effective as UFH, with some meta-analyses and reviews
showing that LMWH is more effective and safer than UFH (Erkens 2010; Leizorovicz 1994; Lensing 1995). Because
LMWH is given subcutaneously once per day and requires no laboratory monitoring it is possible to treat people with
LMWH at home. Although LMWH has been available since 1976, home treatment was not investigated further since it
was first reported in 1988 (Bakker 1988). Rigorous evaluation is required for the home versus in-patient care to
inform policy on alternative strategies for treating DVT. There is potential for home treatment of DVT to save costs
and to be more socially acceptable to the patients. This review aims to update the review which was first published in
2001 and updated in 2007 (Othieno 2007).
Objectives 
To compare the incidence and complications of venous thromboembolism (VTE) in participants treated at home versus
participants treated with standard in-patient hospital regimens. Secondary objectives included patient satisfaction and cost
effectiveness.
Methods 
Criteria for considering studies for this review 
Types of studies 
We included randomised controlled trials (RCTs) in which the participants were randomised to home or in-patient treatment.
Exclusion criteria before randomisation had to be stated and the author's policy regarding protocol violations and withdrawals
known (i.e. intention-to-treat basis).
Types of participants 
We included people with proven VTE in whom there was no contraindication to heparin therapy and whose home
circumstances were adequate. Participants had to have objective evidence of DVT: the accepted and reliable proofs being
duplex scanning and/or venography.
Types of interventions 
We included studies that compared home to hospital management with LMWH (which can be used in either setting) or UFH
(which is used in hospital only). Trials involving a placebo group are not ethically acceptable.
Types of outcome measures 
Primary outcomes
Recurrence of VTE: PE or recurrence of DVT (depending on the length of follow-up)
Venous gangrene
Heparin complications: major and minor bleeding (the former being defined as bleeding within the abdomen, cranium or
eye, or requiring transfusion, or causing a fall in haemoglobin of 2 g/dL or greater)
Death
Ideally, evidence of PE is derived from lung scans, spiral computed tomography (CT) or pulmonary angiography, but as
these were not likely to be widely available, X-rays, ECG and strong clinical signs were considered acceptable. In the event
of death, post-mortem evidence was desirable.
Secondary outcomes
Patient satisfaction and quality of life
Cost effectiveness of treatment (as reported by the individual studies)
We will also report on other outcomes of interest (i.e., post-thrombotic syndrome or length of stay in hospital), when reported
in the individual studies.
Search methods for identification of studies 
Electronic searches 
For this update the Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials.
The Cochrane Vascular Specialised Register (16 March 2017).
The Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2) via the Cochrane Register of Studies
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Online.
See Appendix 1 for details of the search strategy used for CENTRAL.
The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of
MEDLINE Ovid, Embase Ovid, CINAHL and AMED as well as through handsearching relevant journals. The full list of the
databases, journals and conference proceedings searched, as well as the search strategies used, are described in the
Specialised Register section of the Cochrane Vascular module in the Cochrane Library (www.cochranelibrary.com).
In addition, the CIS searched the following trial databases for details of ongoing and unpublished studies (16 March 2017).
See Appendix 2.
World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search
Portal. (apps.who.int/trialsearch)
ClinicalTrials.gov (clinicaltrials.gov)
International Standard Randomised Controlled Trial Number (ISRCTN) registry (www.isrctn.com)
Searching other resources 
Additional articles were identified by reviewing the references of relevant papers resulting from the initial search.
Data collection and analysis 
Selection of studies 
For this update, three review authors (RO, EO, RF) independently selected trials. The final selection of articles was agreed
by discussion and consensus.
Data extraction and management 
Two review authors (RO, EO) independently extracted data from existing and newly included trials using the criteria designed
by Cochrane Vascular. For some references, additional clarification was sought from trial authors. Two review authors (RO,
EO) performed the data entry.
Assessment of risk of bias in included studies
Two review authors (RO, EO) independently assessed the risk of bias of all the included studies using Cochrane's 'Risk of
bias' tool as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We assessed the
included RCTs against the six domains listed below. We rated studies as having 'low risk of bias' (plausible bias unlikely to
seriously alter the results); 'high risk of bias' (plausible bias that seriously weakens confidence in the results); or 'unclear risk
of bias' (plausible bias that raises some doubt about results).
Sequence generation: was the allocation sequence adequately described?
Allocation concealment: was allocation adequately concealed?
Blinding of participants, personnel, and outcome assessors: was knowledge of the allocation intervention adequately
prevented during the study?
Incomplete outcome data: was incomplete outcome data adequately addressed?
Selective outcome reporting: are reports of the study free of suggestion of selective outcome reporting?
Other sources of bias: did the study appear to be free of other problems that could put it at high risk of bias?
Measures of treatment effect
Two review authors (RO, EO) performed the data analysis. Analyses were performed according to the statistical
guidelines for review authors from the Cochrane Vascular Group. Where there were sufficient data, we calculated a
risk ratio (RR) with 95% confidence intervals (CI) using Review Manager software (RevMan 2014).
Unit of analysis issues 
None of the included studies had non-standard designs, such as cross-over trials or cluster-randomised trials. We therefore
did not make any adjustments for measurement effects. The individual participant was the unit of analysis.
Dealing with missing data
We aimed to conduct a complete-case analysis in this Cochrane Review, such that all patients with a recorded outcome were
included in the analysis. We analysed data on an intention-to-treat basis as far as possible. Where data were missing, we
made attempts to obtain them from the original investigators. Where they were unobtainable, we only analysed the available
data, based on the numerator and denominator reported in study results or calculable from reported percentages.
Assessment of heterogeneity 
We examined heterogeneity between the trials by visually examining the forest plots to judge whether there were any
apparent differences in the direction or size of the treatment effect between studies. We also considered the I² and Tau²
statistics and the P value of the Chi² test for heterogeneity. If we identified heterogeneity among the trials (if the value of I²
was greater than 30%, and the value of Tau² was greater than zero or the P value of the Chi² test for heterogeneity was
lower than 0.1), we planned to explore heterogeneity by pre-specified sensitivity analysis as described below.
Assessment of reporting biases
In view of the difficulty in detecting and correcting for publication bias and other reporting biases, we aimed to
minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for
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duplication of data. We planned to use a funnel plot to assess the possibility of small-study effects (a tendency for
estimates of the intervention effect to be more beneficial in smaller studies) for the primary review outcomes when 10
or more studies were included in the meta-analyses (Higgins 2011). We intended to cautiously consider visible asymmetry in
the funnel plot as a possible indication of publication bias.
Data synthesis
We carried out statistical analysis using the Review Manager software (RevMan 2014). We used a fixed-effect meta-analysis
for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e.
where trials were examining the same intervention, and the trials' populations and methods were judged sufficiently similar.
Random-effects meta-analysis would be used if there was clinical heterogeneity sufficient to expect that the underlying
treatment effects differed between trials, or if substantial statistical heterogeneity was detected.
Subgroup analysis and investigation of heterogeneity 
If identified, we planned to explore any possible evidence of heterogeneity within the meta-analyses by subgroup analysis.
There are no other planned subgroup analyses.
Sensitivity analysis
We performed sensitivity analyses by excluding studies that we judged to be at high risk of bias in order to determine the
effect on the overall finding. We also performed sensitivity analysis if a single study carried a majority weight when there
were three or more studies included in an analyses. We preformed additional sensitivity analysis to determine the robustness
of the findings that included data from Koopman 1996; Levine 1996 and Ramacciotti 2004; as we determined that
participants randomised to LMWH were only treated at home as determined by a clinician, and not specifically assigned to
home treatment.
Summary of findings
We presented the main findings of the review results concerning the quality of evidence, the magnitude of effect of the
interventions examined, and the sum of available data for all outcomes of this review (Types of outcome measures) in a
'Summary of findings' table, according to the GRADE principles as described by Higgins 2011 and Atkins 2004.
Evidence is evaluated based on risk of bias of the included studies, inconsistency, indirectness and
imprecision of the data, as well as publication bias. We used the GRADEprofiler (GRADEpro) software to
assist in the preparation of the 'Summary of findings' table (GRADEProGDT 2015). The publication by Ryan 2016 was
utilised to prepare the GRADE ratings.
Results 
Description of studies 
Results of the search
See Figure 1
Included studies
In total, seven studies were eligible for inclusion in this review with a total of 1839 participants (Bäckman 2004; Boccalon
2000; Chong 2005; Daskalopoulos 2005; Koopman 1996; Levine 1996; Ramacciotti 2004). One new study was
identified for this review update (Bäckman 2004). This study had previously been excluded on the grounds that it did not
assess any of the primary outcomes, but after further assessment we decided it should be included as the study did report on
economic data.
Three large trials (Chong 2005; Koopman 1996; Levine 1996) randomised 298 (150 home and 148 hospital), 400
(202 home and 198 hospital), and 500 participants (247 home and 253 hospital) respectively. There were also three
smaller trials (Boccalon 2000; Daskalopoulos 2005; Ramacciotti 2004). Boccalon 2000 reported results on 201 randomised
participants (99 home and 102 hospital); Ramacciotti 2004 reported results on 104 home and 97 hospital randomised
participants and in Daskalopoulos 2005, 108 participants were randomised (55 home and 53 hospital). Bäckman 2004
evaluated and compared direct and indirect medical costs during a three-month period among 131 randomised participants
(65 out-patient/home and 66 in-patient).
Bäckman 2004 did not report on any of the predefined outcomes of this review other than costs and is therefore not included
in any meta-analyses for these outcomes.
The three major trials (Chong 2005; Koopman 1996; Levine 1996) were similar in construction and results, but differed in
their exclusion rates (see Characteristics of included studies; further discussed in Overall completeness and applicability of
evidence). Of the seven trials, only Boccalon 2000 and Bäckman 2004 used LMWH in both treatment arms, the other five
used LMWH in home-treatment arms and UFH in the hospital-treatment arms.
See Characteristics of included studies tables for further details of the included studies
Excluded studies
For this update an additional five studies were excluded (Aujesky 2011; Hull 2009; Modesto-Alapont 2006; Otero 2010; 
Wilson 2003). In total 26 studies were excluded (Aujesky 2011; Belcaro 1999; Blattler 1998; Buller 2004; Conner 1999; 
Fitzmaurice 2000; Frank 1998; Goldhaber 1998; Grau 1998; Grau 2001; Green 1998; Hull 2000; Hull 2002; Hull 2009; 
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Lindmarker 1996; Miles 1998; Modesto-Alapont 2006; O'Shaugnessy 1998; Otero 2010; Pineo 2003; Rymes 2002; Ting
1998; Wells 1998; White 1989; Wilson 2003; Wimperis 1998).
Eight were uncontrolled studies (Conner 1999; Grau 1998; Green 1998; Lindmarker 1996; Miles 1998; O'Shaugnessy 1998; 
Ting 1998; Wimperis 1998). Two trials were retrospective studies (Grau 2001; Rymes 2002). The remaining 16 trials
were excluded for a variety of reasons. Two reported controlled trials were excluded because participants were not
actually randomised but instead treated according to their expressed therapeutic preferences (Blattler 1998; Frank 1998).
Wells 1998 was excluded because it compared patient-administered with nurse-administered injections rather than the
location of treatment. Goldhaber 1998 was excluded because participants randomised to treatment with LMWH in a home
setting were first required to be treated in hospital for a number of days. Otero 2010 and Aujesky 2011 focused on PE and
not DVT. Belcaro 1999 was excluded because it was primarily a trial of formulations of heparin rather than a trial of home
versus hospital treatment. Hull 2000 and Modesto-Alapont 2006 were excluded because they were concerned with
prophylactic regimens using LMWH in patients undergoing hip arthroplasty and those with VTE in obstructive pulmonary
disease, respectively. Pineo 2003 and Hull 2002 were excluded because they investigated two protocols of long-term effects
of LMWH treatment and not location. Two other excluded trials did not have in-patient arms, Wilson 2003 compared
anticoagulant clinics and family clinics, while Hull 2009 compared long-term subcutaneous tinzaparin with initial tinzaparin
followed by long-term warfarin in the community as opposed to home versus inpatients. White 1989 and Fitzmaurice 2000
were concerned with the monitoring of oral anticoagulation at home or in the GP surgery. Buller 2004 compared once daily
LMWH with twice daily doses in the out-patient setting and LMWH with UFH in out-patient setting and not hospital versus
home.
See also Characteristics of excluded studies.
Risk of bias in included studies 
Figure 2 gives an overall view of our assessment of the included studies' risk of bias while Figure 3 shows the 'Risk of bias'
summary presented as percentages across all included studies. See also Characteristics of included studies.
Allocation (selection bias)
We considered the following methods of allocation concealment adequate:
central allocation, including telephone randomisation;
sequentially numbered, opaque, sealed envelopes.
We deemed the risk of bias low if one of these methods was described. We deemed the risk of bias unclear if the study was
described as randomised but the method used for allocation concealment was not described.
All the included trials were reported as randomised controlled trials (RCTs). Random sequence generation was
unclear in six studies (Bäckman 2004; Boccalon 2000; Chong 2005; Koopman 1996; Levine 1996; Ramacciotti 2004
), but adequate in a single trial (Daskalopoulos 2005) as it reported using a computerised process.
Allocation was adequately concealed in four trials (Bäckman 2004; Boccalon 2000; Koopman 1996; Levine 1996).
Daskalopoulos 2005 did not report their method and allocation concealment was not reported in Chong 2005, so both were
rated as unclear risk. In the Ramacciotti 2004 study, randomisation was reportedly done by blocks in an 'open manner',
which we rated as high risk of bias.
Blinding (performance bias and detection bias)
Blinding refers to whether participants and study personnel knew which patients were in hospital and which received
treatment at home. By the nature of this study blinding was never going to be easy to achieve. Five studies were open,
non-blinded studies (Chong 2005; Daskalopoulos 2005; Koopman 1996; Levine 1996; Ramacciotti 2004) and were judged to
be of high risk of bias. Participants in Bäckman 2004 were allowed to change their assigned treatment or leave study after
randomisation but we determined the risk of performance bias as low for the outcomes of this study. Although in Boccalon
2000 no blinding of participant or personnel was reported, both groups received the same treatment. All participants received
an oral anticoagulant for the first three days. The review authors deemed the outcomes were unlikely to have been affected
by lack of blinding of participants or personnel and so was at low risk of bias.
Four studies had independent outcome assessors and were deemed low risk of detection bias (Chong 2005; Daskalopoulos
2005; Koopman 1996; Levine 1996). In three studies blinding of outcome assessors was not reported and therefore
deemed at high risk of detection bias (Bäckman 2004; Boccalon 2000; Ramacciotti 2004).
Incomplete outcome data (attrition bias)
Five of the seven included studies either reported on all participants or adequately described their loss-to-follow up
and were rated as low risk (Bäckman 2004; Chong 2005; Daskalopoulos 2005; Koopman 1996; Levine 1996). Ramacciotti
2004 and Boccalon 2000 had a high rate of attrition and were rated as high risk.
Selective reporting (reporting bias)
We assessed a study as being free of the risk of selective outcome reporting if both the following applied:
the published report included all expected outcomes;
outcomes were reported systematically for all comparison groups, based on prospectively collected data.
We deemed the risk of bias low if both of the criteria were met, unclear if these criteria were not met and high if there was
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evidence that data had been collected on outcomes of interest but were not reported in the study publication.
We did not find any indication suggesting that the outcomes were selectively reported in the included studies so all studies
were rated as low risk.
Other potential sources of bias
We had no concerns regarding other potential sources of bias for two studies (Boccalon 2000; Daskalopoulos 2005). For
Bäckman 2004, Chong 2005, Koopman 1996, Levine 1996 and Ramacciotti 2004 there was insufficient information to judge
whether there was a potential for other bias, so these were rated as unclear risk as each study had a large number of
patients in the LMWH/home treatment group treated in hospital. Koopman 1996, Levine 1996 and Ramacciotti 2004 differed
methodologically as participants randomised to LMWH were only treated at home as determined by a clinician, and not
specifically assigned to home treatment. These studies were evaluated using sensitivity analysis for their impact on evidence
produced through meta-analysis. These issues are further discussed in Overall completeness and applicability of evidence.
Effects of interventions 
A summary of the findings of this review are presented in Summary of findings table 1. The outcomes of the included trials
are summarised in Table 1.
Recurrent VTE (PE or recurrence of DVT)
Six studies reported on this outcome (Boccalon 2000; Chong 2005; Daskalopoulos 2005; Koopman 1996; Levine 1996; 
Ramacciotti 2004). The outcome follow-up time ranged from three months to one year. The pooled results showed a
reduced recurrence of VTE between home and hospital treatment, with home treatment carrying less risk of recurrent VTE
(RR 0.58, 95% CI 0.39 to 0.86; participants = 1708; studies = 6; I2 = 0%; P = 0.007) (Analysis 1.1). The evidence was rated
as low quality due to risk of bias and indirectness concerns.
Venous gangrene
There were no reports of venous gangrene in any of the included studies.
Heparin complications including major and minor bleeding
Six studies reported on this outcome (Boccalon 2000; Chong 2005; Daskalopoulos 2005; Koopman 1996; Levine 1996; 
Ramacciotti 2004). Follow-up of the outcome ranged from 14 days to one year.
On pooling the results of major bleeding, no differences between the home and hospital treatment groups on major bleeding
were seen (RR 0.67, 95% CI 0.33 to 1.36; participants = 1708; studies = 6; I2 = 0%; P = 0.27) (Analysis 1.2). The evidence
was rated as low quality due to risk of bias and indirectness concerns.
For the outcome of minor bleeding no differences between the hospital and home treated arms on minor bleeding were
seen (RR 1.29, 95% CI 0.94 to 1.78; participants = 1708; studies = 6; I2 = 0%; P = 0.11) (Analysis 1.3). The evidence was
rated as low quality due to risk of bias and indirectness concerns.
Death
Six studies included reports on death, with follow up ranging from three months to one year (Boccalon 2000; Chong 2005; 
Daskalopoulos 2005; Koopman 1996; Levine 1996; Ramacciotti 2004). A meta-analysis of the results did not show a
difference in the numbers of deaths between the home and hospital treated groups (RR 0.69, 95% CI 0.44 to 1.09;
participants = 1708; studies = 6; I2 = 0%; P = 0.11) (Analysis 1.4). The evidence was rated as low quality due to risk of bias
and indirectness concerns.
Patient satisfaction and Quality of Life
Three studies included data on quality of life (QoL), (Bäckman 2004; Koopman 1996; Levine 1996). Bäckman 2004 assessed
QoL using the EuroQual tool EQ-5D and found no difference in the mean QoL scores or in the proportion of patients showing
improvement in self-rated health state between the treatment groups. QoL was assessed immediately after treatment and
after three months. A substantial number of patients randomised to in-patient care in this study chose out-patient treatment
for the predominant reason of personal/social preferences. In the Koopman 1996 trial, QoL was measured using the Medical
Outcome Study Short-Form 20 for a generic measure of physical and mental health, as well as adapted version of the
Rotterdam Symptom Checklist, which is specific to thrombosis, and measures were taken at baseline, end of treatment
course, as well as 12 weeks and 24 weeks after treatment. At 24 weeks after treatment over 80% of both trial groups had
completed the QoL questionnaires. Overall, participants showed an improvement in QoL in both groups but two out of six
criteria (physical activity and social functioning) showed an advantage in those in the LMWH group at the completion of initial
treatment, but this difference was not seen at 12 or 24 weeks after treatment. The Levine 1996 study reported on
QoL seven days after treatment using the Medical Outcomes Study Short-Form 36 (SF-36) which reports on eight
physical and mental health domains. Only the social functioning domain showed a greater improvement in patients
treated at home compared with heparin treatment, but there was no difference in the other domains between the two
treatment groups (O'Brien 1999). We could not carry out meta-analysis for this outcome due to heterogeneity in reporting of
QoL, as well as paucity of data reported by the studies.
The quality of evidence for this outcome was rated as very low due to risk of bias, indirectness and heterogeneity of
measurement and reporting.
Cost effectiveness of treatment
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Bäckman 2004, Boccalon 2000, Daskalopoulos 2005 and Koopman 1996 all reported on cost effectiveness of the treatment
comparisons but due to the way the data were presented by the studies no meta-analysis could be performed for this
outcome.
In the Bäckman 2004 study, which reported on costs within three months of treatment, 224 participants were eligible, 131
entered the trial and 124 completed the economic part of the study. Total direct costs were higher for those in the in-patient
strategy group, i.e. Swedish Crown (SEK) 16,400 per patient (Euro 1899) compared to SEK 12,100 per patient (Euro 1405)
in the out-patient (home) strategy group (P < 0.0010).
The Koopman 1996 trial followed participants for six months and the results were used for comparison of the cost of
treatment calculations between the two arms of the trial (van den Belt 1998). There was a 64% saving in those treated with
LMWH as opposed to UFH, largely due to lower hospital costs. The trialists stated that this was a conservative estimate of
the potential reduction in costs. Similarly, an evaluation of those participants entered into the Levine 1996 trial (O'Brien
1999), showed a cost saving of 57%, and followed participants for three months. This latter figure is confirmed by Boccalon
2000 who showed that the mean cost of in-patient treatment over 10 days was more than 55% more expensive compared to
the mean cost of outpatients over the same time period. Similarly, in Daskalopoulos 2005, which reported on 12 months of
follow-up, estimated cost was slightly in favour of the LMWH group due to the significant cut in hospitalisation.
The quality of evidence for this outcome was rated as very low due to risk of bias, indirectness and heterogeneity of
measurement and reporting.
Other outcomes of interest
None of the trials considered the incidence of post-thrombotic syndrome.
Mean hospital stay for patients without events such as bleeding or (suspected) recurrences in Koopman 1996 was 8.1
days for the hospital-treated 'control' group and 2.7 days for the home-treated 'treatment' group. In the other large trial
(Levine 1996), the mean hospital stay was 6.5 days for the hospital-treated control group and 2.1 days for the home-treated
group. Mean hospital stay in the Boccalon 2000 was 9.6 days for the hospital-treated group and one day for the home-
treated group. The Ramacciotti 2004 trial had a mean hospital stay of three days for home-treated patients and
seven days for the hospital-treated patients. Three studies did not report duration of hospital stay (Bäckman 2004; Chong
2005; Daskalopoulos 2005).
Thirty-six per cent of participants in the Koopman 1996 trial were treated entirely at home, 39% had a short hospital stay and
25% were entirely hospital treated. Fifty per cent of participants in the Levine 1996 trial were treated entirely at home. In the
Daskalopoulos 2005 trial, no patient allocated to receive treatment with LMWH underwent any hospitalisation.
Seventy-seven percent of participants in the home arm (LMWH group) of the Chong 2005 trial were admitted to hospital.
Twelve percent were released on the day of admission, 34% were kept for one day and 31% were kept for two or more
nights. The Ramacciotti 2004 trial reported hospitalisation for all hospital-treated patients and 64% of home-treated patients.
Heterogeneity, subgroup analysis and sensitivity analysis
We found the heterogeneity in the pooled effect estimates to be very low and did not have reason to further
investigate. When we performed sensitivity analysis we found no difference in the evidence when the studies
with high risk of bias were removed (Ramacciotti 2004). There were no analyses that had a majority weight by a single study,
so no sensitivity analyses was performed on these criteria. Sensitivity analysis was performed by evaluating the impact of the
Koopman 1996 Levine 1996 and Ramacciotti 2004 trials due to the issue that participants randomised to LMWH were only
treated at home as determined by a clinician, and not specifically assigned to home treatment. This sensitivity analysis did
not change the findings of the meta-analyses.
Discussion 
Summary of main results
This review presents low-quality evidence that patients treated at home with LMWH are less likely to have recurrence of
VTE, compared to those treated in an in-patient (hospital) setting. No differences in major or minor bleeding events or
mortality were seen (all low-quality evidence), indicating that home treatment is no worse for these outcomes when
compared with in-patient treatment.
Overall completeness and applicability of evidence
While the results of this review are promising there are several concerns with the applicability of the evidence. Primarily, a
large number of the participants in the home treatment group were not solely treated at home. Also, the treatment
comparison was not always superior in the larger trials, and finally, there were a large number of eligible participants
excluded prior to randomisation, raising concerns with applicability.
Many of the participants randomised to home treatment with a LMWH were not actually treated fully at home but hospitalised
for some or all of the treatment period (See Table 2 for more details). Only 40% (Bäckman 2004), 23% (Chong 2005
), 36% (Koopman 1996) 48.5% (Levine 1996) and 36% (Ramacciotti 2004), of those randomised to home treatment
were treated wholly at home, and this makes the trials' results difficult to interpret. For three trials the participants
that were randomised to the LMWH treatment, as opposed to the UFH, could be treated at home or in an in-patient
setting at the discretion of the clinicians or investigators (Koopman 1996; Levine 1996; Ramacciotti 2004). This creates the
concern that the data collected and reported in the meta-analyses may not directly speak to the question at hand. In order to
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address these issues we conducted extensive sensitivity analyses and found there was no difference in our findings when
the findings of these studies were excluded. This issue is not just a problem with these few trials but an overall, and possibly
insurmountable one, as the nature of DVT and its complications may require in-patient treatment, even if a person is deemed
acceptable for home treatment. However, these trials have shown that patients treated at home with LMWH are less likely to
have recurrence of VTE compared to their counterparts treated in the hospital with UFH or LMWH. Also, participants were
found to have preferred treatment at home. These concerns would most likely lead to a dilution of the conclusions of the
review.
In the three major RCTs (Chong 2005; Koopman 1996; Levine 1996), UFH in hospital was compared with LMWH at
home. A more methodologically sound trial would have compared LMWH in both groups and would have been
justified by the many trials and three meta-analyses (Erkens 2010; Leizorovicz 1994; Lensing 1995) showing that LMWH is
at least as effective as UFH.
Another factor limiting the conclusions of the review was the very high pre-randomisation exclusion rate reported by
several of the trials (Boccalon 2000; Koopman 1996; Levine 1996). Koopman 1996 reported an exclusion of 31% of eligible
participants and Levine 1996 reported 67%. Similarly, high exclusion rates were reported by Boccalon 2000 (78%), and
Bäckman 2004 (42%). The exclusion criteria were very diffuse and could have been less strict. Daskalopoulos 2005
presented a contrasting low exclusion rate (7%). Ramacciotti 2004 and Chong 2005 did not report on pre-randomisation
exclusions, except for three participants in the Chong 2005 trial who were enrolled but not randomised because they did not
receive the study treatment or did not provide treatment-related data.
Although we have included 'economic analysis' as an outcome, a comprehensive economic analysis is beyond the
scope/expertise of this review, so we have reported only on limited data available from the included studies.
Other issues that may affect applicability of our review are the limited number of participants from developing countries and
the fact that no high-quality randomised control trials have been published after 2005.
Trends in the treatment of VTE have been changing recently with practitioners moving away from UFH and using
more LMWHs and the newer class of direct oral anticoagulants (DOACs). Treatment with LMWHs and DOACs
have been shown to be efficacious with no increase in clinically relevant complications (Robertson 2015; Robertson 2017
). While UFH treatment is not going to disappear completely, due to its monitoring requirements and subsequent costs
there has been a trend in practitioners moving away from its usage and embracing LMWH and DOACs. With DOACs,
however, clinicians treating VTE have to reckon with their complexity, which include appropriate dose selection for the
relevant indication, avoidance of drug-drug and drug-disease interactions, and consideration of dose adjustments in
specific clinical situations, such as organ dysfunction (Finks 2016). This review did not evaluate any studies that included the
use of DOACs, such as rivaroxaban or dabigatran, as no such studies met our inclusion criteria. We therefore have limited
evidence from this review to discuss their use in detail.
Quality of the evidence
Strengths of the evidence include the consistency and homogeneity of the results from the individual studies as well as the
sufficient number of participants and events included for each outcome. However, the evidence generated in the review was
downgraded to low quality due to concerns with risk of bias of the individually included studies as well as with indirectness of
the data due to the issues of participants randomised to home treatment being hospitalised, as discussed in the above
section. A major concern with risk of bias was selection bias: all seven included studies were at unclear or high risk for either
concerns with random sequence generation or allocation concealment. Although minimising performance bias would be very
difficult due to the open nature of the treatment, making blinding of the participants and personnel nearly impossible, these
issues could be addressed in other ways such as keeping the treatment drugs consistent between interventions or also
demonstrating more stringent control of detection bias. Risk of bias concerns led us to downgrade the evidence by one level.
These concerns reduce the robustness of the findings. See Summary of findings table 1 for further information.
Sensitivity analysis was conducted by evaluating the strength of the evidence in light of the risk of bias issues as well
concerns with indirectness, and we found that the findings did not change when studies with high risk of bias, or studies that
may not have directly contributed to the objective of the review, were removed.
Publication bias was not investigated for the review because less than 10 studies were included in the individual meta-
analyses. Less than 10 studies will not produce robust results in the funnel plots used to investigate publication bias.
Potential biases in the review process
All possible measures to reduce potential biases were adhered to during the review process, including conducting a
comprehensive search, double data extraction and grading of the evidence. All attempts were made to identify relevant
studies and disagreements were discussed thoroughly.
Agreements and disagreements with other studies or reviews
The results of uncontrolled trials encompass a considerable body of evidence (Table 3), particularly in relation to practical
questions (see Implications for research). An observational study that included 334 patients concluded that community-
based treatment of thromboembolism was safe and effective (Hyers 2007). Home treatment has also been
investigated in specific pathological communities including cancer patients, and found to be a suitable alternative to in-
patient care (Ageno 2005).
In the UK, some local health authorities (Trusts) have published the results of uncontrolled studies. Swindon Trust
reported 373 patients referred to the program of whom 32% had proven DVT and 37.5% were treated wholly or
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partially at home (Green 1998). Chertsey Trust reported on 1093 referrals of which 160 were proven to have
DVT. All but one i.e. 159 patients, were home-treated (O'Shaugnessy 1998). There were no complications apart from
two minor bleeds. The savings to the Chertsey Trust was estimated as £320,000 over 22 months. In a combined
presentation to the American Thoracic Society, three trusts reported managing 966 patients with DVT of whom only
10% were admitted to hospital (Miles 1998). In Norwich, 447 patients were referred over a six-month period, scans
were positive in 30% and, of these, 20% were considered unsuitable for home treatment (Wimperis 1998). Thus, 105 were
treated and five had to be re-admitted - two with suspected PE (scans negative), one with PE, one with stroke, and one with
an unrelated illness.
A study from Melbourne (Ting 1998), presented 100 patients with proven DVT. Fifty-three patients had proximal
thrombosis and were admitted for one day for investigation, including lung scan: 16 scans were positive although
the patients were asymptomatic and the result did not affect their management at home. The 47 patients with
distal thrombosis were treated entirely at home. There was initial extension of clot in 13.2% of distal and 2.7% of
proximal thromboses but at follow-up scans at six months, 60.7% of distal and 18.5% of proximal thromboses had
completely resolved. The only complications were six minor bleeds. The numbers of patients referred but cleared
of DVT, and the numbers rejected by the protocol were not mentioned. In a Swedish study (Lindmarker 1996), 434 patients
with DVT were treated in hospital for three days before discharge home on treatment. Three patients had proven PE: there
was one major bleed and 16 minor ones. There were no deaths in the acute stage and no extension of thromboses. In Grau
1998, 39 out of 71 patients with DVT were treated at home. There was no instance of PE and only one minor bleed.
These trials all reported worthwhile cost savings. Only one uncontrolled study reported on patient satisfaction (Conner 1999).
Seventy-nine per cent were happy to be treated at home, 12% would have preferred hospital and nine per cent had no
preference.
Although not based on evidence from randomised controlled trials, cost savings in favour of home treatment have been
shown wherever calculated. Hospital Episode Statistics for the UK for 1993 (Griffin 1996), show 17,000 admissions for
PE and 25,000 for DVT with an average in-patient stay of 7.2 days. At an estimated cost of £200 per in-patient day
(1998 figures), hospitalisation costs alone amount to £60,480,000. If this could be reduced to, say, two days in 75% of
cases at a cost of £12,600,000, a saving of £47,880,000 on bed costs per annum is realisable. Although it was not in
the remit of this review, it is worth noting that surveillance of participants up to four years after randomisation to home or
hospital regimens showed no difference between the groups (Grau 2001).
Regarding the results of quality of life outcomes reported in Bäckman 2004, a similar preference was observed in two thirds
of patients in Blattler 1998, (excluded from our review as it was not an RCT), who challenged hospital confinement
and stated that they would not choose hospitalisation another time. The Blattler trial also reported that their home
treatment group was free of symptoms a day earlier and returned to work a week earlier than the hospital group (Blattler
1998).
Authors' conclusions 
Implications for practice 
This review presents low-quality evidence that patients treated at home with LMWH are less likely to have recurrence of VTE
compared to those treated in hospital. No clear differences in major or minor bleeding complications, or mortality were seen
(low-quality evidence), indicating treatment at home with LMWHs is not more harmful than treatment in an in-patient setting
with LMWHs or UFHs. Despite the limitations in the reviewed trials, there is low-quality evidence to suggest that home
treatment of DVT is more effective than standard hospital treatment.
Implications for research 
It is unlikely that definitive evidence of the safety of home treatment will be forthcoming for reasons addressed in the
discussion. This is underscored by the fact that no further high-quality randomised control trials published after 2005
have been identified in our search. Also, treatment of thromboembolism with LMWHs is being incorporated into local
health authority guidelines that include at home administration practices (East Lancashire Health Economy 2015; Wong
2014). Further information will consist of accumulation of a larger database of uncontrolled studies that can only be
compared with historical controls. There may be anecdotal notes of failure but, as these will be rare, it is possible they will not
be published.
It has been suggested by Baron 1999 that patients should be allocated on a triage basis: (1) standard in-patient regimen for
those with intercurrent illness or massive VTE; (2) partial home treatment for those diagnosed in hospital but fit enough for
discharge; and (3) those treated completely at home. The ideal trial would compare LMWH only in each arm, would exclude
25% or fewer participants from entry into the trial, and would present the results in three groups. These issues should be
given further examination.
Some practical issues remain to be resolved.
Should the patient be admitted at all if suitable for home treatment?
Should LMWH be given on suspicion or only on confirmation of the diagnosis?
How would the treatment comparison alter using newer direct oral anticoagulants compared with more traditional LMWH?
Should exclusion criteria be relaxed to favour greater entry to home treatment? For example, should a healthy pregnancy
preclude home treatment?
Should a screening test such as D-dimer levels be used?
Should the system be controlled by the traditional physician's team or should specialist anticoagulant nurses be trained
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and, if so, will there still be a lead clinician to accept overall responsibility?
Development of local guidelines which contain clinical prediction rules, biomarkers and imaging which can be used to
tailor therapy to the severity of the disease.
Training community healthcare workers to administer and monitor treatment progress.
Acknowledgements 
We extend our acknowledgement to Ivor Schraibman, Elizabeth Royle, and Alan Milne for authoring the original draft of this
review. We would like to thank Mayada Abu Affan for her contribution to the 2007 update of the review and the Cochrane
Vascular editorial base for their support and assistance with updating this review.
Contributions of authors 
EO: independently selected the articles, assessed studies for inclusion and assessed the methodological quality of selected
trials, extracted data, data entry, analysis and drafted the report, evaluated the evidence of the review, contributed to the
discussion of the final report of the review
RO: independently selected the articles, assessed studies for inclusion and assessed the methodological quality of selected
trials, extracted data, and contributed to the discussion of the final report of the review
RF: data entry, analysis and drafted the report, evaluated the evidence of the review, contributed to the discussion of the final
report of the review
Declarations of interest 
RO: none known
EO: none known
RF: none known
Differences between protocol and review 
The methodological quality of the included studies is assessed using Cochrane's Risk of bias tool (Higgins 2011) instead of
the previously used method by Jadad 1996. We have added a summary of findings table and assessed the quality of
the evidence according to GRADE (Atkins 2004).
The secondary outcome of patient satisfaction was broadened to include quality of life as this outcome is becoming more
commonly used and is well accepted.
Outcomes 'PE' and 'recurrent DVT' renamed as 'Recurrence of VTE'.
Published notes 
Characteristics of studies
Characteristics of included studies 
Boccalon 2000
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Methods Study design: randomised controlled trial
Exclusions post-randomisation: one patient withdrew consent following randomisation,
7 patients withdrew due to severe complications (3 DVT extensions, 4 major
haemorrhages)
Losses to follow up: 38 participants did not complete the 6 months follow up (with
those being treated in hospital twice as likely to withdraw)
Intention to treat analysis: not indicated
 
Participants Country: France
Setting: home or hospital
N: 204 randomised, 201 included (102 hospital, 99 home) representing 11.8% of those
eligible
Age: mean 63.8 ± 14.1 years, range 18 to 85 years
Sex: 113 males: 88 females
Inclusion criteria: confirmed diagnosis (by ultrasonography or venography) of proximal
DVT not more than 30 days before enrolment
Exclusion criteria: thrombus in the inferior vena cava, a floating thrombus, history of
DVT within the previous 6 months, DVT with symptomatic PE, a clinical condition
requiring hospitalisation, contraindication to anticoagulant treatment, pregnancy,
heparin treatment within the 48 hours preceding inclusion, home or hospital treatment
were impossible for any reason, participant lived too far away from the trial centre,
written consent was not given
Participants were also examined, though not necessarily excluded, for risk factors for
DVT, including previous thromboembolism, varicose veins, immobilization, surgery,
trauma, cancer, use of oral contraceptive, known or inherited clotting disorders, other
co-morbidities such as cardiovascular disease with right ventricular failure
 
Interventions Treatment: sc injection of LMWH (dalteparin sodium, enoxaparin sodium or nadroparin
calcium as chosen by the attending physician) at the recommended dose followed by
anticoagulant for 6 months at home
Control: sc injection of LMWH (dalteparin sodium, enoxaparin sodium or nadroparin
calcium as chosen by attending physician) at the recommended dose followed by
anticoagulant for 6 months initially in hospital for 10 ± 2 days then at home
Anticoagulants: oral VKA or fluindione, 20 mg/day for the first 3 days, followed by
regimen to maintain INR between 2.0 and 3.0 for up to 6 months
Participants were also given compression stockings and were encouraged to return to
physical activity according to a schedule approved by the general practitioner and
nurse
 
Outcomes Primary: recurrent VTE, PE, major bleeding
Secondary: death, minor bleeding, economic analysis
Duration of follow-up: six months
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Not stated
 
Allocation concealment (selection
bias)
Low risk Sealed envelopes used
 
Blinding of participants and
personnel (performance bias)
Low risk Although no blinding of participant or personnel was reported both groups
received the same treatment. All patients received an oral anticoagulant
for the first 3 days. Outcome is unlikely to have been affected by lack of
blinding of participants or personnel
 
Blinding of outcome assessment
(detection bias)
High risk Blinding of outcome assessors not reported. Outcome could have been
influenced by lack of blinding
 
Incomplete outcome data (attrition
bias)
High risk 38 participants did not complete the 6 months follow up (with those being
treated in hospital twice as likely to withdraw)
 
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
 
Other bias Low risk No other potential bias identified
 
Bäckman 2004
Methods Study design: randomised multicentre trial
Exclusions post-randomisation: 7 patients excluded (5 randomised to inpatient
treatment refused to cooperate, and 2 randomised to outpatient/home treatment had a
drug reaction and haematuria, respectively
Losses to follow-up: none
Intention to treat analysis: yes
 
Participants Country: Sweden
Setting: inpatient or outpatient/home
N: 224 met inclusion criteria, 131 randomised (66 inpatient, 65 outpatient/home)
representing 58% of those eligible
Age: mean 66 (33 - 87) years, inpatient group; 67 (25 - 91) years, outpatient/home
group
Sex: male/female ratio, 34/34 inpatient group; 34/31 outpatient group
Inclusion criteria: acute symptomatic DVT confirmed by phlebography or ultrasound in
patients aged 18 years and older presenting at the emergency department
Exclusion criteria: not clearly stated
 
Interventions All patients were provided with intervention stockings. Both groups were treated with
LMWH administered sc once daily, adjusted for body weight, for at least 5 days until
prothrombin time was < 25% (INR > 2.0) for at least 1 day
Outpatient/home: treatment included a daily visit to the outpatient department at a
primary care centre or else a visit by the district nurse at the patient's home,
depending on the local circumstances or patient preference
Inpatient: patients were admitted to the ward
 
Outcomes Direct medical and direct non-medical costs
Duration of follow-up three months
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk The method used to generate the random sequence is not described by
the authors
 
Allocation concealment (selection
bias)
Low risk Randomisation was performed centrally by means of codes in envelopes
in batches of 20 in accordance with Zelen 1979
 
Blinding of participants and
personnel (performance bias)
Low risk Although participants were allowed to change their assigned treatment
or leave study after randomisation, the review authors determined the
risk of performance bias as low
 
Blinding of outcome assessment
(detection bias)
High risk Not described; outcomes could have been influenced by lack of blinding
 
Incomplete outcome data (attrition
bias)
Low risk No missing data
 
Selective reporting (reporting bias) Low risk Pre-specified outcomes included
 
Other bias Unclear risk Insufficient information to determine if other potential bias exist; only
40% of participants randomised to treatment with LMWH were actually
treated at home
 
Chong 2005
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Methods Study design: randomised parallel-group open study
Exclusions post-randomisation: 63 (20%) were not included in the primary outcome
analysis
Losses to follow-up: 45 had no analysis at 24 weeks
Intention-to-treat analysis: yes
 
Participants Countries: Australia, New Zealand, Poland, South Africa
Setting: outpatient or hospital
N: 301 enrolled; 298 randomised (148 hospital, 150 home)
Age: 18+ years
Sex: 156 males, 142 females
Inclusion criteria: diagnosis of symptomatic lower extremity DVT (proximal or distal)
confirmed by either contrast venography and/or ultrasonography, be suitable for
treatment in an outpatient setting, be prepared to self administer daily sc injections, life
expectancy > 6 months
Exclusion criteria: 1) received therapeutic doses of heparin for more than 24 hours
before randomisation; 2) clinically overt signs or symptoms of PE or evidence of PE
on lung scanning or pulmonary angiography; 3) impending venous gangrene; 4)
previous HIT or another hypersensitivity reaction to heparin; 5) a platelet count < 50 x
10/9 per litre; treatment with fibrinolytics or oral anticoagulants within the previous 5
days, or with other investigational therapeutic agents within the previous 4 weeks; 6)
pregnancy or lactation; 7) any clinical significant medical condition other than DVT that
would prevent the patient from being discharged from hospital
 
Interventions Treatment: once daily sc injection of LMWH enoxaparin 1.5 mg/kg for a minimum of 5
days plus 10 mg of warfarin for 3 months with dose adjusted to achieve and maintain
the INR above 2 and within range accepted by the investigator
Control: 5000 IU bolus of UFH for a minimum of 5 days plus 10 mg warfarin started on
day 1 of the treatment for 3 months
 
Outcomes Primary: efficacy endpoint: incidence of symptomatic recurrent DVT
Safety endpoint: incidence of adverse effect, major or minor bleeding during the first
14 days
Secondary: incidence of PE, recurrent VTE
Duration of follow up: 24 weeks
 
Notes  
Risk of bias table
IS39 Home versus in-patient treatment for deep vein thrombosis
16 / 38
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Did not report use of adequate random sequence generation
 
Allocation concealment (selection
bias)
Unclear risk Did not report use of adequate concealment technique
 
Blinding of participants and
personnel (performance bias)
High risk Treatment was not blinded
 
Blinding of outcome assessment
(detection bias)
Low risk Assessors were independent of the study and investigators and
unaware of the treatments that patients were receiving
 
Incomplete outcome data (attrition
bias)
Low risk All outcome data reported
 
Selective reporting (reporting bias) Low risk All pre-specified primary and secondary safety endpoints were reported
 
Other bias Unclear risk Insufficient information to determine if other potential bias exist; only
23% of participants randomised to treatment with LMWH were actually
treated exclusively at home
 
Daskalopoulos 2005
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Methods Study design: prospective randomised trial
Exclusions post randomisation: 6 patients withdrew consent following randomisation
Losses to follow-up: none
Intention to treat analysis: yes
 
Participants Country: Greece
Setting: outpatient or hospital
N: 108 randomised (55 LMWH, 53 UFH)
Age: 18 years and over, range 23 to 95, mean 58.6 years
Sex: 61 female, 41 male
Inclusion criteria: acute proximal DVT confirmed by colour duplex ultrasound scan not
more than 1 week onset
Exclusion criteria: segmental DVT restricted to infrapopliteal deep veins or calf
muscles as determined by duplex ultrasonography, symptomatic or clinically
suspected PE, history of recently diagnosed (within 12 months) DVT or PE, patient
already on anticoagulant therapy, bleeding tendency objectively confirmed,
hypersensitivity to heparin preparations or coumarin derivatives, uncontrolled
hypertension, history of recently diagnosed (less than 1 month) cerebrovascular
accident, intracranial artery aneurysm, infectious endocarditis, thrombocytopenia,
active peptic ulcer, hepatic or renal failure, history of asthma, recent spinal or epidural
anaesthesia or intraspinal paracentesis (less than 5 days), recent surgery (less than 5
days), recently performed thrombolysis or under antiplatelet therapy, body weight less
than 35 kg, pregnancy, illicit drug addiction, altered mental status or impaired cognitive
function with inability to comply with study protocol
 
Interventions Treatment: single sc injection of LMWH (tinzaparin sodium) in a weight adjusted dose
(175 anti Xa IU/Kg) daily for 6 months
Control: iv bolus of 5000 IU UFH followed by iv infusion of UFH for 5 to 7 days. APTT
was measured after 4 hours of the initiation of heparin administration and was
repeated 6 hours thereafter to reach the therapeutic range (ratio: 1.5 to 2.5)
Oral anticoagulant was commenced on the 3rd day following UFH therapy
 
Outcomes Primary: recanalisation of the thrombosed veins, major events
Secondary: recurrent DVT, PE, major bleeding, minor bleeding, thrombocytopenia,
death
Duration of follow-up: 12 months
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Randomisation was by means of a computer schedule
 
Allocation concealment (selection
bias)
Unclear risk Not reported
 
Blinding of participants and
personnel (performance bias)
High risk The study was open-label
 
Blinding of outcome assessment
(detection bias)
Low risk Because a double blind study was not feasible, all objective diagnostic
tests were interpreted by specialists including Coagulation Unit staff and
radiology staff who were not involved in the study
 
Incomplete outcome data (attrition
bias)
Low risk All outcome data were reported
 
Selective reporting (reporting bias) Low risk All pre-defined endpoints data were reported
 
Other bias Low risk No other potential bias was identified
 
Koopman 1996
Methods Study design: randomised controlled trial
Exclusions post- randomisation: two (both withdrew consent, one from each group)
Losses to follow up: two patients in each group were lost to follow up at 12 weeks
Intention to treat analysis: yes
 
Participants Countries: The Netherlands, France, Italy, New Zealand, Australia
Setting: home or hospital
N: 400 randomised (202 LMWH, 198 UFH)
Age: 59 ± 17 years LMWH group, 62 ± 16 years UFH group
Sex: 203 males: 197 females
Inclusion criteria: acute symptomatic proximal DVT proven by venography or duplex
scan
Exclusion criteria: VTE within previous 2 years, suspected PE at presentation,
geographic inaccessibility, PTS, less than 18 years old, pregnancy, life expectancy
less than 6 months, previous treatment with heparin for more than 24 hours
 
Interventions Treatment: twice daily injections of LMWH (nadroparin calcium (Fraxiparine) at a dose
adjusted for patient's weight) at home when appropriate; Patients were instructed by
nurse on how to administer the injections themselves
Control: UFH (APTT adjusted dose, continuous iv infusion of 1250 IU per hour after
initial iv bolus of 5000 IU) in hospital
Duration: minimum 5 days, maximum 24 weeks
Oral anticoagulation: warfarin commenced on day 1 and continued for 3 months, dose
adjusted to give INR 2.0 to 3.0
 
Outcomes Primary: Symptomatic recurrent VTE
Secondary: major haemorrhage, death, quality of life comparisons, comparison of
costs (in-patient versus home)
Duration of follow-up: six months
 
Notes  
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Method of random sequence generation not reported
 
Allocation concealment (selection
bias)
Low risk Allocation was by means of a central 24-hour telephone service
 
Blinding of participants and
personnel (performance bias)
High risk Unblinded trial
 
Blinding of outcome assessment
(detection bias)
Low risk Objective testing was done blindly as well as documentation of all
potential outcome events were assessed by an independent adjudication
committee whose members were unaware of the treatment assignments
 
Incomplete outcome data (attrition
bias)
Low risk All losses to follow up were reported
 
Selective reporting (reporting bias) Low risk All pre-specified outcome measures were reported
 
Other bias Unclear risk Insufficient information to determine if other potential bias exist; only 36%
of participants randomised to treatment with LMWH were actually treated
at home
 
Levine 1996
IS39 Home versus in-patient treatment for deep vein thrombosis
20 / 38
Methods Study design: randomised controlled trial
Exclusions post-randomisation: not stated
Losses to follow up: none
Intention to treat analysis: not indicated but analysis included all randomised
participants
 
Participants Country: Canada
Setting: home or hospital
N: 500 randomised (247 LMWH, 253 UFH)
Age: mean 57 ± 17 years LMWH group, 59 ± 15 years UFH group
Sex: 301 males: 199 females
Inclusion criteria: acute proximal DVT proven on venography or duplex scan
Exclusion criteria: two or more previous episodes of DVT or PE, active bleeding, active
peptic ulcer, coagulation disorder, symptomatic PE, possibility of non-compliance,
contraindications to LMWH, pregnancy, pre-treatment with heparin for more than 48
hours, inability to make follow up visits due to geographical inaccessibility, presence of
known deficiency of anti-thrombin III, protein C or protein S
 
Interventions Treatment: sc LMWH (enoxaparin 1 mg per kg body weight twice a day) primarily at
home
Control: UFH (APTT adjusted dose, continuous iv infusion of 20,000 IU after initial iv
bolus of 5000 IU) in hospital
Duration: minimum 5 days
Anticoagulants: warfarin sodium started on evening of day 2 and continued for at least
3 months. First dose 10 mg, thereafter adjusted to maintain INR between 2.0 and 3.0
 
Outcomes Primary: symptomatic recurrent DVT or PE within 90 days of randomisation, major
bleeding, minor bleeding during study period and up to 48 hours after discontinuation
of study medication
Secondary: death, economic evaluation
Duration of follow-up: three months
 
Notes  
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Method of random sequence generation not reported
 
Allocation concealment (selection
bias)
Low risk Assignment of treatment was over the telephone from a central site
 
Blinding of participants and
personnel (performance bias)
High risk Unblinded
 
Blinding of outcome assessment
(detection bias)
Low risk Testing and assessment of recurrent VTE and bleeding were conducted
by a committee unaware of the treatment assignments.
 
Incomplete outcome data (attrition
bias)
Low risk There were no losses to follow-up
 
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported
 
Other bias Unclear risk Insufficient information to determine if other potential bias exist; only
48.5% of participants randomised to treatment with LMWH were actually
treated at home
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Ramacciotti 2004
Methods Study design: randomised, open label, multicenter clinical trial
Exclusions post-randomisation: not stated
Losses to follow-up: 53.6% at 6 months of follow up
Intention to treat analysis: not indicated but analysis included all randomised
participants
 
Participants Country: Brazil
Setting: home or hospital
N: 201 randomised (104 enoxaparin, 97 UFH)
Age (years): mean 64 for home, 44 for hospitals
Sex: 69 Males, 132 Females
Inclusion criteria: age greater than or equal to 18 years, weight greater than or equal to
50 kg and < 110 kg, DVT symptoms for greater than or equal to 10 days, proximal
lower limb DVT (confirmed by duplex ultrasound or venography), ready access to local
health service, capable of using enoxaparin at home
Exclusion criteria: history of HIT or allergy to heparin, haemorrhagic diathesis, surgery
within 7 days, symptoms of PE, bilateral DVT, survival prognosis < 6 months, hepatic
or renal failure, received therapeutic doses of UFH or LMWH for greater than or equal
to 24 hrs in the previous 48 hrs, patients in hospital for another reason, with stay
anticipated to last > 3 days, initial platelet count < 100,000/ml, uncontrolled
hypertension with DBP greater than or equal to 180, initial APTT > 1.3 time the normal
value, INR > 1.5 at enrolment, indication for thrombolysis or venous thrombectomy
 
Interventions Treatment: once daily sc injection of LMWH enoxaparin at a dose of 1.5 mg/kg for 5 to
10 days given at home or in hospital at the discretion of the health care provider
Control: iv bolus injection of 5000 IU of UFH followed by iv 500 IU/kg/day adjusted to
maintain an APTT of 1.5 to 2.5 times the normal value for 5 to 10 days in hospital
Anticoagulant: all patients received warfarin (with a targeted INR 2 to 3) for at least 3
months, starting at day 1 or 2 of treatment
 
Outcomes Primary: recurrent DVT, PE
Secondary: major and minor bleeding
Duration of follow-up: six months
 
Notes  
Risk of bias table
IS39 Home versus in-patient treatment for deep vein thrombosis
22 / 38
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Randomisation was by block 1:1 at each centre to ensure balanced in
each treatment arm but method of random sequence generation was not
reported
 
Allocation concealment (selection
bias)
High risk Each investigator received the randomisation scheme specifying the
treatment allocation for each patient enrolled in the study. Thus the
investigator could foresee assignments and thus introduce selection bias
 
Blinding of participants and
personnel (performance bias)
High risk Open-label
 
Blinding of outcome assessment
(detection bias)
High risk Not reported
 
Incomplete outcome data (attrition
bias)
High risk Only 32.7% of enoxaparin and 46.4% UFH patients were followed up
after 6 months
 
Selective reporting (reporting bias) Low risk All pre-specified safety endpoints were reported
 
Other bias Unclear risk Insufficient information to determine if other potential bias exist; only 36%
of participants randomised to treatment with enoxaparin were actually
treated at home
 
Footnotes
APTT: activated partial thromboplastin time
DBP; diastolic blood pressure
DVT: deep vein thrombosis
HIT: heparin-induced thrombocytopenia
INR: international normalised ratio
IU: international units
iv: intravenous
LMWH: low molecular weight heparin
PE: pulmonary embolism
PTS: post-thrombotic syndrome
PTT: partial thromboplastin time
sc: subcutaneous
UFH: unfractionated heparin
VKA: vitamin K antagonist
VTE: venous thromboembolism
Characteristics of excluded studies 
Aujesky 2011
Reason for exclusion Assessed effectiveness, safety and efficacy of outpatient versus inpatient care for
patient with acute PE and not DVT
 
Belcaro 1999
Reason for exclusion Participants were randomised to different forms of heparin rather than to home or
hospital treatment
 
Blattler 1998
Reason for exclusion Although this study is published as an RCT the methodology does not meet the criteria
for an RCT
 
Buller 2004
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Reason for exclusion Compared once daily LMWH with twice daily doses in the outpatient setting and not
hospital versus home
 
Conner 1999
Reason for exclusion Uncontrolled trial
 
Fitzmaurice 2000
Reason for exclusion This study was concerned with the monitoring of oral anticoagulation at home or in the
GP surgery
 
Frank 1998
Reason for exclusion Although this study is published as an RCT the methodology does not meet the criteria
for an RCT
 
Goldhaber 1998
Reason for exclusion Participants randomised to home care with LMWH were first required to be treated in
hospital before being discharged
 
Grau 1998
Reason for exclusion Not a randomised trial
 
Grau 2001
Reason for exclusion Retrospective study
 
Green 1998
Reason for exclusion Uncontrolled trial
 
Hull 2000
Reason for exclusion Trial concerned with prophylactic regimens using LMWH in patients undergoing hip
arthroplasty
 
Hull 2002
Reason for exclusion Trial concerned with evaluating two long term LMWH treatment protocols
 
Hull 2009
Reason for exclusion Not home versus inpatient care, both groups of patients treated outside hospital. Usual
care was defined as tinzaparin for five days or more followed by warfarin for 12 weeks
 
Lindmarker 1996
Reason for exclusion Uncontrolled trial
 
Miles 1998
Reason for exclusion Uncontrolled trial
 
Modesto-Alapont 2006
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Reason for exclusion Investigated the use of LMWH administered at home for the prevention of VTE in
patients with severe chronic obstructive pulmonary disease
 
O'Shaugnessy 1998
Reason for exclusion Uncontrolled trial
 
Otero 2010
Reason for exclusion Focused on PE and not DVT
 
Pineo 2003
Reason for exclusion Trial concerned with evaluating two long term LMWH treatment protocols
 
Rymes 2002
Reason for exclusion Retrospective study
 
Ting 1998
Reason for exclusion Uncontrolled trial
 
Wells 1998
Reason for exclusion Controlled trial of nurse versus patient injection. Not related to admission or home
treatment
 
White 1989
Reason for exclusion This trial was concerned with the monitoring of oral anticoagulation at home or in the
GP surgery
 
Wilson 2003
Reason for exclusion Study design not home versus in-patient, anticoagulant clinics versus family physician
clinic. Intervention was oral anticoagulant and not LMWH. The study population was
anyone who required warfarin for at least three months and not specifically DVT
 
Wimperis 1998
Reason for exclusion Uncontrolled trial
 
Footnotes
DVT: deep vein thrombosis
LMWH: low molecular weight heparin
PE: pulmonary embolism
RCT: randomised controlled trial
UFH: unfractionated heparin
VTE: venous thromboembolism
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of findings tables
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How does treatment of DVT at home compared to treatment of DVT in hospital?
Patient or population: people with a diagnosed DVT
Setting: hospital and home
Intervention: treatment of DVT at home with LMWH1
Comparison: treatment of DVT in hospital with UFH or LMWH2
Outcomes № of
participants
(studies)
Follow up
Quality of
the
evidence
(GRADE)
Relative
effect
(95%
CI)
Anticipated absolute
effects* (95% CI)
Comments
Risk with
treatment of
DVT in
hospital
Risk
difference
with
Treatment of
DVT at home
Recurrence of VTE
follow-up: range 3
months to 12
months
1708
(6 RCTs)
⊕⊕⊝⊝
LOW 3,4 
RR 0.58
(0.39 to
0.86)
Study population  
74 per
1,000
31 fewer per
1,000
(45 fewer to
10 fewer)
Venous gangrene see comment This outcome was not reported by any of the
included studies
Major bleeding
follow-up: range 14
days to 12 months
1708
(6 RCTs)
⊕⊕⊝⊝
LOW 3,4
RR 0.67
(0.33 to
1.36)
Study population  
21 per
1,000
7 fewer per
1,000
(14 fewer to
8 more)
Minor bleeding
follow-up: range 14
days to 12 months
1708
(6 RCTs)
⊕⊕⊝⊝
LOW3,4
RR 1.29
(0.94 to
1.78)
Study population  
72 per
1,000
21 more per
1,000
(4 fewer to
56 more)
Death
follow-up: range 3
months to 12
months
1708
(6 RCTs)
⊕⊕⊝⊝
LOW3,4
RR 0.69
(0.44 to
1.09)
Study population  
49 per
1,000
15 fewer per
1,000
(28 fewer to
4 more)
Patient
satisfaction/Quality
of life
follow-up: range 7
days to 6 months
1031
(3 RCTs)
⊕⊝⊝⊝
VERY
LOW3,4,5
-  
See comment
Two studies reported greater improvements
in QoL in patients treated at home compared
with in-patient treatment, the third study
reported a large number of participants
chose to switch from in-patient care to home
based care, suggesting it is the patient's
preferred option
Cost effectiveness 6
follow up: range 10
days to 6 months
834
(4 RCTs)
⊕⊝⊝⊝
VERY
LOW3,4,5
-  
See comment
One study carried out a randomised
economic evaluation and reported total
direct costs were higher for those in the
inpatient strategy group, i.e. Swedish Crown
(SEK) 16,400 per patient (Euro 1,899)
compared to SEK 12,100 per patient (Euro
1,405) in the outpatient (home) strategy
group (P < 0.0010). This was supported by
three other studies who reported on costs
*We calculated the assumed risk of the hospital treatment group from the average risk in the hospital treatment group (i.e.
the number of participants with events divided by total number of participants of the hospital treatment group included in the
meta-analysis). The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; DVT: Deep vein thrombosis; LMWH: low molecular weight heparin, RR: Risk ratio; UFH:
unfractionated heparin, VTE: Venous thromboembolism
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GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate
of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different
from the estimate of effect
Footnotes
1 Home treatment refers to treatment for DVT with a LMWH that occurs outside of a hospital or in-patient setting and can
include the medication being administered by the participant or by a carer
2 Hospital treatment refers to treatment for DVT with either a LMWH or UFH in a hospital or in-patient setting which is
administered by care staff
3 Downgraded one level due to risk of bias from unclear randomisation techniques and blinding measures in a majority of the
included studies
4 Downgraded one level due to indirectness because most of the included studies had a low number of participants actually
treated at home with a LMWH and many were treated in hospital
5 Downgraded one level due to heterogeneity because the included studies used different methods and time points in which
to gather information of this outcome
6 We are reporting on the cost effectiveness analysis reported in the included studies. We have not carried our an economic
analysis ourselves
Additional tables 
1 Summary of outcomes
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Study Setting
Number
participants
entered
Heparin
type
Mean
hospital
stay (days)
Recurrence of
VTE (%)
Major
bleeding
(%)
Minor
bleeding
(%)
Death
(%)
Mean total direct
costs per
participant
Bäckman 2004                  
  Hospital 65 LMWH 3.6 - - - - SEK 16,400
  Home 66 LMWH 1.6 - - - - SEK 12,100
Boccalon 2000                  
  Hospital 102 LMWH 9.5 2.0 2.0 10.8 2.0 Fr 20,932
  Home 99 LMWH 1.4 1.0 2.0 17.2 0 Fr 9,230
Chong 2005                  
  Hospital 148 UFH - 9.5 2.0 11.5 1.4 -
  Home 150 LMWH - 2.7 0 10.0 1.3 -
Daskalopoulos
2005
                 
  Hospital 53 UFH - 11.3 7.5 5.7 3.8 -
  Home 55 LMWH - 9.1 3.6 5.5 1.8 -
Koopman 1996                  
  Hospital 198 UFH 8.1 8.6 2.0 7.6 8.1 -
  Home 202 LMWH 2.7 6.9 0.5 13.4 6.9 -
Levine 1996                  
  Hospital 253 UFH 6.5 6.7 1.2 2.3 6.7 -
  Home 247 LMWH 2.1 5.3 2.0 2.4 4.5 -
Ramacciotti
2004
                 
  Hospital 97 LMWH 3 2 2 12 - -
  Home 104 UFH 7 7 3 9 - -
Footnotes
LMWH: low molecular weight heparin
UFH: unfractionated heparin
VTE: venous thromboembolism
2 Percentage of patients treated at home
Patients Bäckman2004
Boccalon
2000
Chong
2005
Daskalopoulos
2005
Koopman
1996
Levine
1996
Ramacciotti
2004
Randomised (N) 131 201 298 108 400 500 201
Excluded after randomisation (%) 5.3 18.9 20 5.5 0 0 0
Participants randomised to home/LMWH
treat that were actually treated at home
(not hospitalised) (%)
40* 74 23** 100*** 36 48.5 36
Footnotes
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*Bäckman 2004 reported 40% of those randomised to home treatment remained at home, and 40% were hospitalised; it is
unclear what happened with the remaining 20%; 36 randomised participants changed treatment, 26 of whom changed from
hospital to home and 10 from home to hospital
**Chong 2005 23% of those randomised to home treatment were exclusively treated at home, 12% were hospitalised and
discharged within a day, 35% were hospitalised for one night, 23% for two nights and 8% for three or more nights
***Daskalopoulos 2005 initially reported "Patients allocated to receive treatment with LMWH underwent no hospitalizations at
all", but later in the text they state "The number of major events requiring hospitalization was significantly lower in the LMWH
group", making it unclear if those randomised to LMWH were exclusively treated at home
LMWH: low molecular weight heparin
3 Uncontrolled trials - patient demographics
Author ReferralsPositive scans% home treated
Grau 1998 - 71 55.0
Green 1998 373 119 37.5
Lindmarker 1996 - 434** 100.0
Miles 1998 - 966 90.0
O'Shaugnessy 1998 1093 160 99.9
Ting 1998 - 53* 100.0
Wimperis 1998 447 134 80.0
Total   1451  
Footnotes
* Excluding distal thrombosis
** 3 days hospital treatment before discharge
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Data and analyses 
1 Treatment of DVT at home versus treatment of DVT in hospital
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Recurrence of VTE 6 1708 Risk Ratio(M-H, Fixed, 95% CI) 0.58 [0.39, 0.86]
1.2 Major bleeding 6 1708 Risk Ratio(M-H, Fixed, 95% CI) 0.67 [0.33, 1.36]
1.3 Minor bleeding 6 1708 Risk Ratio(M-H, Fixed, 95% CI) 1.29 [0.94, 1.78]
1.4 Death 6 1708 Risk Ratio(M-H, Fixed, 95% CI) 0.69 [0.44, 1.09]
Figures
Figure 1
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Caption
Study flow diagram.
Figure 2
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Caption
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
Figure 3
Caption
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included
studies.
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1 Anticoagulant feedback, 14 February 2011
Summary
Feedback received on this review, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial
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Appendices 
1 CENTRAL search strategy
#1 MESH DESCRIPTOR Thrombosis 1261
#2 MESH DESCRIPTOR Thromboembolism 919
#3 MESH DESCRIPTOR Venous Thromboembolism 257
#4 MESH DESCRIPTOR Venous Thrombosis EXPLODE ALL TREES 2036
#5 (thrombus* or thrombopro* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*):TI,AB,KY 18960
#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE ALL TREES 746
#7 (PE or DVT or VTE):TI,AB,KY 4979
#8 ((vein* or ven*) near thromb*):TI,AB,KY 6702
#9 (blood near3 clot*):TI,AB,KY 2963
#10 (pulmonary near3 clot*):TI,AB,KY 5
#11 (lung near3 clot*):TI,AB,KY 4
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 24595
#13 MESH DESCRIPTOR Outpatients 983
#14 MESH DESCRIPTOR Inpatients 703
#15 MESH DESCRIPTOR Patient Care EXPLODE ALL TREES 48022
#16 MESH DESCRIPTOR Ambulatory Care 2843
#17 MESH DESCRIPTOR Home Nursing 253
#18 MESH DESCRIPTOR Hospitalization EXPLODE ALL TREES 10891
#19 MESH DESCRIPTOR Outpatient Clinics, Hospital 541
#20 in-patient:TI,AB,KY 4947
#21 inpatient:TI,AB,KY 5166
#22 hospitali*:TI,AB,KY 25539
#23 bed-ridden:TI,AB,KY 20
#24 bedridden:TI,AB,KY 107
#25 home:TI,AB,KY 19783
#26 out-patient:TI,AB,KY 1246
#27 outpatient:TI,AB,KY 15589
#28 ambulatory*:TI,AB,KY 14873
#29 domicil*:TI,AB,KY 383
#30 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR#26 OR #27 OR #28 OR #29 108891
#31 #12 AND #30 3043
2 Trials registries searches
Clinicaltrials.gov
44 studies found for: embolism AND home
WHO
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809 records for 256 trials for: embolism AND home
ISRCTN
18 records for: embolism AND home
Graphs
1 - Treatment of DVT at home versus treatment of DVT in hospital
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